ESMO 2020 | Pembrolizumab plus chemotherapy for esophageal cancer: KEYNOTE-590

Elizabeth C. Smyth, MD, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the results of the KEYNOTE-590 (NCT03189719) Phase III trial. Pembrolizumab plus chemotherapy was compared to chemotherapy alone in treatment-naive esophageal cancer. Both endpoints, progression-free survival and overall survival, were met. However, further research is needed for adenocarcinomas as response to treatment is not as long as squamous cell carcinomas. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).